AP NEWS
Press release content from Business Wire. The AP news staff was not involved in its creation.
PRESS RELEASE: Paid content from Business Wire
Press release content from Business Wire. The AP news staff was not involved in its creation.

6-Hour Virtual Seminar on Tougher Import Rules for FDA Imports in 2019 (22 May, 2019 - 11:00 EDT) - ResearchAndMarkets.com

May 17, 2019

DUBLIN--(BUSINESS WIRE)--May 17, 2019--

The “6-Hour Virtual Seminar on Tougher Import Rules for FDA Imports in 2019” webinar has been added to ResearchAndMarkets.com’s offering.

Importing FDA regulated products requires careful planning before you even start. Registration, product compliance, record and data submission must be exactly correct or your product will be detained.

Likewise, the U.S. Customs and Border Protection (CBP) must be precise or your entry is not going anywhere. Some mistakes are common, others reflect a lack of understanding of how FDA and Customs and Border Protection (CBP) operate a joint program.

The logistics of importing products complicates the process further and you must know the consequences of your decisions. Some problems can cost you time and money, especially when you do not work promptly with the FDA. If you end up with having your entry “refused.” There is no appeal. Then you face the possibility of additional steep fines by CBP and be blocked from the U.S. market.

Why You Should Attend

Firms typically run aground with importing FDA regulated products because they do not understand how to prepare, conduct and report information in accord with FDA requirements. That mire of activity starts before you even ship a product to the U.S. If the exporter and importer do not follow the procedures or fail to submit correct information, the road forward has an expensive and time-consuming toll.

A failure to do things correctly will create a “bad actor” image, which is very hard to undo and FDA does not forget, somewhat like a regulatory elephant. It is true. If you understand FDA’s and CBP’s import program, your business can operate in a competitive way. If you do not, your customers, foreign suppliers, and stockholders will see the consequences and not be forgiving.

Who Should Attend?

  • Regulatory Affairs Directors
  • Software Designers / Specification Developers
  • Production Managers
  • Quality Assurance Directors
  • In-house Legal Counsel

Agenda

  1. FDA’s legal authority and burden of proof
  2. FDA registration, product information and the software PREDICT screening program
  3. CBP entry information and the Automated Commercial Environment (ACE) program
  4. Tariffs, fees, bonded warehouses, and free trade zones (FTZ)
  5. Special labeling requirements, e.g., bulk active pharmaceuticals, research use, investigational use, and return for repair
  6. FDA “holds,” “detentions” and what to do immediately
  7. Negotiating with FDA

For more information about this webinar visit https://www.researchandmarkets.com/r/h49g2o

View source version on businesswire.com:https://www.businesswire.com/news/home/20190517005192/en/

CONTACT: ResearchAndMarkets.com

Laura Wood, Senior Press Manager

press@researchandmarkets.com

For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900

Related Topics:Pharmaceuticals,Medical Devices

KEYWORD:

INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL

SOURCE: Research and Markets

Copyright Business Wire 2019.

PUB: 05/17/2019 06:57 AM/DISC: 05/17/2019 06:57 AM

http://www.businesswire.com/news/home/20190517005192/en